Price
$1.26
Increased by +15.60%
Dollar volume (20D)
1.14 M
ADR%
11.13
Shares float
83.94 M
Shares short
9.49 M [11.31%]
Shares outstanding
93.00 M
Market cap
101.38 M
Beta
2.44
Price/earnings
N/A
20D range
0.75 1.32
50D range
0.66 1.32
200D range
0.66 3.00

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.

The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus.

It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.

Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 9, 25 -0.44
Increased by +5.41%
-0.45
Increased by +2.22%
Mar 11, 25 -0.39
Increased by +0.79%
-0.40
Increased by +3.28%
Nov 7, 24 -0.38
Decreased by -217.92%
-0.45
Increased by +15.11%
Aug 7, 24 -0.44
Increased by +9.17%
-0.44
Increased by +0.91%
May 7, 24 -0.46
Increased by 0.00%
-0.41
Decreased by -12.06%
Mar 11, 24 -0.39
Increased by +11.36%
-0.37
Decreased by -5.41%
Nov 7, 23 -0.12
Increased by +72.73%
-0.42
Increased by +71.43%
Aug 8, 23 -0.48
Decreased by -9.09%
-0.49
Increased by +2.04%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 2.35 M
Decreased by -3.13%
-39.99 M
Increased by +3.01%
Decreased by -1.70 K%
Decreased by -0.12%
Dec 31, 24 2.08 M
Decreased by -41.62%
-35.49 M
Decreased by -2.85%
Decreased by -1.71 K%
Decreased by -76.19%
Sep 30, 24 2.02 M
Decreased by -91.45%
-34.68 M
Decreased by -246.77%
Decreased by -1.71 K%
Decreased by -3.95 K%
Jun 30, 24 3.46 M
Decreased by -7.75%
-37.70 M
Decreased by -27.70%
Decreased by -1.09 K%
Decreased by -38.43%
Mar 31, 24 2.43 M
Decreased by -30.64%
-41.23 M
Decreased by -65.02%
Decreased by -1.70 K%
Decreased by -137.92%
Dec 31, 23 3.56 M
Decreased by -3.63%
-34.51 M
Decreased by -27.85%
Decreased by -969.79%
Decreased by -32.66%
Sep 30, 23 23.66 M
Increased by +616.38%
-10.00 M
Increased by +62.62%
Decreased by -42.27%
Increased by +94.78%
Jun 30, 23 3.75 M
Decreased by -10.42%
-29.52 M
Decreased by -18.25%
Decreased by -786.13%
Decreased by -32.01%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY